http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002042679-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1019fb51220a23555730ab96763d96d5 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16211 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A90-10 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5044 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-502 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2000-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e2027f9a1b9a0a7036ebd1379e09760 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b430bfc60469e76092dea81c987e2e6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0384387c25058493c68796c78a3cc777 |
| publicationDate | 2002-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2002042679-A1 |
| titleOfInvention | Method of managing the chemotherapy of patients who are HIV positive based on the phenotypic drug sensitivity of human HIV strains |
| abstract | The present invention is drawn to A method of managing HIV chemotherapy of patients who are HIV positive, which comprises transfecting a cell line susceptible to infection by HIV with a sequence from the pol gene of HIV, which sequence encodes a desired target enzyme, obtained by isolating viral RNA from a sample of a biological material from a patient and reverse transcribing the desired region of said pol gene, and a HIV-DNA construct from which said sequence has been deleted, culturing said transfected cells so as to create a stock of chimeric viruses providing an indication of the resistance profile of the circulating virus, assessing the phenotypic sensitivity of said chimeric viruses to an inhibitor of said enzyme encoded by the pol gene of HIV and assigning a value thereto, constructing a data set comprising said value for chimeric virus sensitivity and the corresponding value for a chimeric wild-type strain of HIV, repeating the sensitivity assessment for at least two further inhibitors and thereby constructing at least three such data sets in total, representing said data sets in two dimensional or three dimensional graphical form such that the difference between the chimeric and wild-type sensitivities in the case of each data set provides a visual measure of the resistance of the chimeric stock to treatment by the inhibitor in question, and selecting the optimum inhibitor(s) on the basis of the graphical representation of the resistance so measured. |
| priorityDate | 1996-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 598.